Key result
Real-world mavacamten linked to low rates of treatment interruption for LVEF under 50%.
Why the study?
Does mavacamten prescribed under a REMS program have a low rate of safety events (LVEF reduction) in patients with symptomatic obstructive hypertrophic cardiomyopathy?
Observational (n=6,000)
Does mavacamten prescribed under a REMS program have a low rate of safety events (LVEF reduction) in patients with symptomatic obstructive hypertrophic cardiomyopathy?
Real-world data from the first 22 months of the REMS program suggest that mavacamten is safe in clinical practice, with low rates of LVEF reduction requiring treatment interruption.
We describe the feasibility and experience of the first 22 months of the Risk Evaluation and Mitigation Strategy program for prescribing mavacamten in >6000 patients with symptomatic obstructive hypertrophic cardiomyopathy. The need for temporary interruption for LVEF <50% was low, including for patients on therapy ≥1 year, with even fewer LVEF reductions associated with heart failure requiring hospitalization.
No takes yet. Share an insight, caveat, or question.
Desai et al. (2024) conducted an observational in symptomatic obstructive hypertrophic cardiomyopathy (n=6,000). Mavacamten was evaluated on temporary interruption for LVEF <50%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: